Phase 3 Knee OA Trial Recruiting and Dosing in AUS & US
Filed with ASX · · 3 pages · English
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Appendix 4E and 2025 Annual Report
- June 2025 Quarterly Activities Report & Appendix 4C
- Paradigm Secures US$27M to Advance Phase 3 OA Trial
- Paradigm Strengthens OA Pipeline with Strategic Acquisition
- PAR Receives US Ethics Approval for Phase 3
Later from Paradigm Biopharmaceuticals
- September 2025 Quarterly Activities Report & Appendix 4C
- Drawdown of Tranche 2 under the Convertible Note Facility
- Phase 3 Knee OA Trial Recruitment Update
- iPPS Phase 2 Biomarker Results Published in Leading Journal
- December 2025 Quarterly Activities Report & Appendix 4C
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals